Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.

Although there was an apparent trend towards shorter disease-free survival with increasing HER-2 gene copy numbers or increasing HER-2 FISH ratios, the differences were not statistically significant.

also in 709 other papers

A retrospective analysis was performed in 33 patients with HER-2-positive metastatic breast cancer receiving trastuzumab ( Gullo et al , 2009 ): patients with a high HER-2/CEP17 ratio had shorter time-to-progression and OS than did those with lower ratios ( Gullo et al , 2009 ), although the difference did not reach statistical significance, probably because of the sample size and the relatively short follow-up.

also in 111,027 other papers